PropertyValue
is ?:annotates of
?:authorAffiliation
  • [\'Centre for Neuroscience Studies, Department of Biomedical and Molecular Sciences, Queen\'s University, Kingston, ON, Canada; Department of Psychiatry, Queen\'s University, Kingston, ON, Canada. Electronic address: ndml@queensu.ca.\', \'D\'OR Institute for Research & Education, RJ, Brazil; Institute of Medical Biochemistry Leopoldo de Meis, Federal University of Rio de Janeiro, RJ, Brazil. Electronic address: fernanda.aragao@idor.org.\', \'Centre for Neuroscience Studies, Department of Biomedical and Molecular Sciences, Queen\'s University, Kingston, ON, Canada; Department of Psychiatry, Queen\'s University, Kingston, ON, Canada; D\'OR Institute for Research & Education, RJ, Brazil; Institute of Medical Biochemistry Leopoldo de Meis, Federal University of Rio de Janeiro, RJ, Brazil.\', \'D\'OR Institute for Research & Education, RJ, Brazil; Institute of Medical Biochemistry Leopoldo de Meis, Federal University of Rio de Janeiro, RJ, Brazil; Institute of Biophysics Carlos Chagas Filho, Federal University of Rio de Janeiro, RJ, Brazil.\']
?:citedBy
  • -1
?:creator
?:doi
?:doi
  • S0028-3908(22)00082-X10.1016/j.neuropharm.2022.109023
?:hasPublicationType
?:journal
  • Neuropharmacology
is ?:pmid of
?:pmid
?:pmid
  • 35257690
?:publication_isRelatedTo_Disease
?:rankingScore_SJR
  • 2.043
?:rankingScore_hIndex
  • 146
is ?:relation_isRelatedTo_publication of
?:title
  • Inflammation at the crossroads of COVID-19, cognitive deficits and depression.
?:type
?:year
  • 2022

Metadata

Anon_0  
expand all